Related references
Note: Only part of the references are listed.Elevated CSF neurofilament proteins predict brain atrophy: A 15-year follow-up study
Axel Petzold et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity
Jens Kuhle et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Elevated CSF neurofilament proteins predict brain atrophy: A 15-year follow-up study
Axel Petzold et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity
Jens Kuhle et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
Jens Kuhle et al.
NEUROLOGY (2015)
N-Acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis
Alessandro Trentini et al.
JOURNAL OF NEUROLOGY (2014)
Natalizumab in progressive MS Results of an open-label, phase 2A, proof-of-concept trial
Jeppe Romme Christensen et al.
NEUROLOGY (2014)
Neurofilaments as biomarkers in multiple sclerosis
Charlotte E. Teunissen et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Axonal Damage in Relapsing Multiple Sclerosis is Markedly Reduced by Natalizumab
Martin Gunnarsson et al.
ANNALS OF NEUROLOGY (2011)
Neurofilament light as a prognostic marker in multiple sclerosis
Jonatan Salzer et al.
MULTIPLE SCLEROSIS JOURNAL (2010)